The recovery and half-life of VIII: C in the plasma of severely haemophilic patients was measured by one-stage and two-stage assays after injection of two Factor VIII concentrates (Hemofil, Hyland and Fraction I-O, Kabi). Plasma volumes were measured with an Evans� Blue technique, and both concentrates and post-infusion samples were measured against the same plasma standard.
There was a highly significant difference in recoveries estimated by the two assay methods. The one-stage assays gave the most consistent results, in that the average recovery was 100%, whereas the two-stage assays gave only about 80% of the value expected from in vitro assays. There was no difference in recoveries between the two concentrates.
The two-stage assays gave a slightly shorter half-life than the one-stage assays, and the half-life of Hemofil was also shorter than that of Fraction I-O.
References
1
Adelson E.
1964. The survival of factor VIII and factor IX in normal humans. In
Brinkhous KM.
(Ed.)
The Haemophilias. p 197 University of North Carolina Press; Chapel Hill:
2
Biggs R.
1964; The turnover of factors II, VIII, IX and X in patients deficient in these factors. Thrombosis et Diathesis Haemorrhagica Suppl 13: 201
3
Biggs R,
Matthews JM.
1966. The plasma concentration of factor VIII in the treatment of haemophilia. In
Biggs R,
Macfarlane RG.
(Eds.)
Treatment of Haemophilia and Other Coagulation Disorders. Blackwell; Oxford: p 107
5
Blombäck B,
Blombäck M.
1958; Purification of antihaemophilic globulin. I. Some studies on the stability of the antihaemophilic globulin activity in fraction 1-0 and a method for its partial separation from fibrinogen. Arkiv för Kemi 12: 387
6
Johnson AJ,
Karpatkin MH,
Newman J.
1971; Clinical investigation of intermediate- and high-purity antihaemophilic factor (factor VIII) concentrates. British Journal of Haematology 21: 21
7
Kirkwood TB L,
Rizza CR,
Snape TJ,
Rhymes I,
Austen DE G.
1977; Identification of sources of inter-laboratory variation in factor VIII assay. British Journal of Haematology 37: 559
10
Nilsson I-M,
Blomback M,
Von Francken I.
1957; On an inherited autosomal hemorrhagic diathesis with antihemophilic globulin deficiency and prolonged bleeding time. Acta Medica Scandinavica 159: 35
11
Nilsson I-M,
Blomback M,
Ramgren O.
1962; Haemophilia in Sweden: VI. reatment of haemophilia with the human antihaemophilic factor preparation (fraction I-O). TActa Medica Scandinavica Suppl 379: 61
14
Nilsson I-M,
Hedner U.
1977; Characteristics of various factor VIII concentrates used in treatment of haemophilia A. British Journal of Haematology 37: 543
15
Nilsson I-M,
Barrowcliffe TW,
Kirkwood TB L,
Miller-Andersson M,
Seghatchian MJ.
1977; Problems of quantitation of FVIII:C activity. 6th Congress of the International Society for Thrombosis and Haemostasis (Abstract) Thrombosis and Haemostasis 38: 25
16
Over J,
Sixma JJ,
Poucet-De Bruine MH M,
Trieschaigg AM C,
Vlooswuk RA A,
Beeser-Visser NH,
Bouma BN.
1978; Survival of 125Iodine-labelled factor VIII in normals and patients with classic haemophilia. Journal of Clinical Investigation 62: 223
17
Owen
Jr C,
Bowie EJ W.
1975. Infusion therapy in hemophilia A and B. In
Brinkhous KM,
Hemker HC.
(Ed.)
Handbook of Hemophilia. Part II. p 487 Excerpta Medica; Amsterdam:
18
Peake IR,
Bloom AL.
1978; Immunoradiometric assay of procoagulant factor VIII antigen in plasma and serum and its reduction in haemophilia. Lancet 1: 473
19
Pool JG,
Robinson J.
1959; Observations on plasma banking and transfusion procedures for haemophilic patients using a quantitative assay for antihaemophilic globulin (AHG). British Journal of Haematology 5: 24
22
Wagner RH,
Mclester WD,
Smith M,
Brinkhous KM.
1964; Purification of antihemophilic factor (factor VIII) by aminoacid precipitation. Thrombosis et Diathesis Haemor- rhagica 11: 64
